Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2
- PMID: 9443863
- PMCID: PMC1376797
- DOI: 10.1086/301670
Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2
Abstract
Breast cancer-susceptibility genes BRCA1 and BRCA2 have recently been identified on the human genome. Women who carry a mutation of one of these genes have a greatly increased chance of developing breast and ovarian cancer, and they usually develop the disease at a much younger age, compared with normal individuals. Women can be tested to see whether they are carriers. A woman who undergoes genetic counseling before testing can be told the probabilities that she is a carrier, given her family history. In this paper we develop a model for evaluating the probabilities that a woman is a carrier of a mutation of BRCA1 and BRCA2, on the basis of her family history of breast and ovarian cancer in first- and second-degree relatives. Of special importance are the relationships of the family members with cancer, the ages at onset of the diseases, and the ages of family members who do not have the diseases. This information can be elicited during genetic counseling and prior to genetic testing. The carrier probabilities are obtained from Bayes's rule, by use of family history as the evidence and by use of the mutation prevalences as the prior distribution. In addressing an individual's carrier probabilities, we incorporate uncertainty about some of the key inputs of the model, such as the age-specific incidence of diseases and the overall prevalence of mutations. There is some evidence that other, undiscovered genes may be important in explaining familial breast cancer. Users of the current version of the model should be aware of this limitation. The methodology that we describe can be extended to more than two genes, should data become available about other genes.
Similar articles
-
Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history.J Natl Cancer Inst. 1997 Feb 5;89(3):227-38. doi: 10.1093/jnci/89.3.227. J Natl Cancer Inst. 1997. PMID: 9017003
-
BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age.J Med Genet. 2001 Jun;38(6):361-8. doi: 10.1136/jmg.38.6.361. J Med Genet. 2001. PMID: 11389159 Free PMC article.
-
Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study.Genet Epidemiol. 2001 Jul;21(1):1-18. doi: 10.1002/gepi.1014. Genet Epidemiol. 2001. PMID: 11443730
-
Breast cancer susceptibility genes. BRCA1 and BRCA2.Medicine (Baltimore). 1998 May;77(3):208-26. doi: 10.1097/00005792-199805000-00006. Medicine (Baltimore). 1998. PMID: 9653432 Review.
-
Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.JAMA. 1997 Mar 26;277(12):997-1003. JAMA. 1997. PMID: 9091675 Review.
Cited by
-
Optimal breast cancer risk reduction policies tailored to personal risk level.Health Care Manag Sci. 2022 Sep;25(3):363-388. doi: 10.1007/s10729-022-09596-2. Epub 2022 Jun 10. Health Care Manag Sci. 2022. PMID: 35687269 Free PMC article.
-
Utilization of religious coping strategies among African American women at increased risk for hereditary breast and ovarian cancer.Fam Community Health. 2009 Jul-Sep;32(3):218-27. doi: 10.1097/FCH.0b013e3181ab3b53. Fam Community Health. 2009. PMID: 19525703 Free PMC article.
-
Cancer genetic counselor information needs for risk communication: a qualitative evaluation of interview transcripts.J Pers Med. 2013;3(3):238-50. doi: 10.3390/jpm3030238. J Pers Med. 2013. PMID: 24358447 Free PMC article.
-
Ethnic, racial and cultural identity and perceived benefits and barriers related to genetic testing for breast cancer among at-risk women of African descent in New York City.Public Health Genomics. 2011;14(6):356-70. doi: 10.1159/000325263. Epub 2011 May 3. Public Health Genomics. 2011. PMID: 21540561 Free PMC article.
-
No Evidence for the Pathogenicity of the BRCA2 c.6937 + 594T>G Deep Intronic Variant: A Case-Control Analysis.Genet Test Mol Biomarkers. 2018 Feb;22(2):85-89. doi: 10.1089/gtmb.2017.0187. Epub 2018 Jan 22. Genet Test Mol Biomarkers. 2018. PMID: 29356578 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous